drugset / Trial / NCT00948493

Treatment Use of Generex Oral-lyn™ in Patients With Diabetes

NCT00948493

Expanded access No longer available Generex Biotechnology Corp.

Summary

The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of diabetes, and who are not eligible to participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). This protocol is intended as a substitute for the Single Patient IND mechanism to obtain Generex Oral-lyn™.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Generex Oral-lyn™ Unknown Oral